ALGN vs AZN
Align Technology vs AstraZeneca PLC — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
AZN
AstraZeneca PLC
56
Watch
| Metric | ALGN | AZN |
|---|
| AI Score |
73
|
56
|
| Price |
$172.86
|
$158.74
|
| P/E Ratio |
30.03×
|
23.81×
|
| ROE |
10.1%
|
21.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
79.3%
|
| Debt / Equity |
0.03×
|
0.64×
|
| Dividend Yield |
0.0%
|
1.3%
|
| RSI (14) |
55.1
|
33.8
|
| Beta |
1.653
|
0.211
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus AZN.
ALGN leads by 17 points.
ALGN scores 73/100 (Buy) versus AZN at 56/100 (Watch).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
AZN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical